Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)

We report the case of a 19-year-old woman who received a complete vaccine program by Gardasil. After one year, Greiner HPV test revealed HPV51 positivity. This case report highlights the limits of the vaccine, and the need to have a clinical follow up of patients despite the vaccination program.

Detalles Bibliográficos
Autores principales: Halfon, Philippe, Ravet, Sophie, Khiri, Hacène, Penaranda, Guillaume, Lefoll, Carole
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046010/
https://www.ncbi.nlm.nih.gov/pubmed/21769258
http://dx.doi.org/10.4137/CCRep.S6177
_version_ 1782198905096634368
author Halfon, Philippe
Ravet, Sophie
Khiri, Hacène
Penaranda, Guillaume
Lefoll, Carole
author_facet Halfon, Philippe
Ravet, Sophie
Khiri, Hacène
Penaranda, Guillaume
Lefoll, Carole
author_sort Halfon, Philippe
collection PubMed
description We report the case of a 19-year-old woman who received a complete vaccine program by Gardasil. After one year, Greiner HPV test revealed HPV51 positivity. This case report highlights the limits of the vaccine, and the need to have a clinical follow up of patients despite the vaccination program.
format Text
id pubmed-3046010
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-30460102011-07-18 Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®) Halfon, Philippe Ravet, Sophie Khiri, Hacène Penaranda, Guillaume Lefoll, Carole Clin Med Insights Case Rep Case Report We report the case of a 19-year-old woman who received a complete vaccine program by Gardasil. After one year, Greiner HPV test revealed HPV51 positivity. This case report highlights the limits of the vaccine, and the need to have a clinical follow up of patients despite the vaccination program. Libertas Academica 2010-12-16 /pmc/articles/PMC3046010/ /pubmed/21769258 http://dx.doi.org/10.4137/CCRep.S6177 Text en © 2010 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Case Report
Halfon, Philippe
Ravet, Sophie
Khiri, Hacène
Penaranda, Guillaume
Lefoll, Carole
Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)
title Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)
title_full Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)
title_fullStr Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)
title_full_unstemmed Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)
title_short Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)
title_sort incident hpv 51 infection after prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine gardasil/silgard(®)
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046010/
https://www.ncbi.nlm.nih.gov/pubmed/21769258
http://dx.doi.org/10.4137/CCRep.S6177
work_keys_str_mv AT halfonphilippe incidenthpv51infectionafterprophylacticquadrivalenthumanpapillomavirustypes61116and18l1viruslikeparticlevaccinegardasilsilgard
AT ravetsophie incidenthpv51infectionafterprophylacticquadrivalenthumanpapillomavirustypes61116and18l1viruslikeparticlevaccinegardasilsilgard
AT khirihacene incidenthpv51infectionafterprophylacticquadrivalenthumanpapillomavirustypes61116and18l1viruslikeparticlevaccinegardasilsilgard
AT penarandaguillaume incidenthpv51infectionafterprophylacticquadrivalenthumanpapillomavirustypes61116and18l1viruslikeparticlevaccinegardasilsilgard
AT lefollcarole incidenthpv51infectionafterprophylacticquadrivalenthumanpapillomavirustypes61116and18l1viruslikeparticlevaccinegardasilsilgard

Ejemplares similares